Allopurinol Therapy

Introduction to Allopurinol Therapy

The American College of Physicians recommends immediate discontinuation of allopurinol in patients who develop jaundice, as it may represent a potentially life-threatening drug reaction with significant mortality risk, based on strong evidence from multiple sources 1

Carriers of the HLA-B*58:01 genetic variant have a significantly increased risk (ORs of 80-580) of developing jaundice while on allopurinol therapy, according to the American Journal of Kidney Diseases 1
Patients with renal impairment, pre-existing liver disease, and concomitant medications (e.g., ampicillin/amoxicillin) are at increased risk of developing adverse reactions, as suggested by various studies 2, 3
Additional HLA risk alleles associated with allopurinol hepatotoxicity include HLA-B53:01 and HLA-A34:02, particularly in African Americans 1
Patients of East Asian descent, particularly those with the HLA-B*58:01 genetic variant, are at increased risk of developing adverse reactions to allopurinol 1

Jaundice typically develops 2-6 weeks after starting allopurinol, with a median time to onset of approximately 52 days 1
Associated symptoms often include fever, skin rash (maculopapular, sometimes scaly or exfoliative), eosinophilia, elevated liver enzymes, and systemic symptoms affecting multiple organs 1

The European League Against Rheumatism recommends considering febuxostat as an alternative therapy for gout if allopurinol cannot be tolerated, with evidence from the Annals of the Rheumatic Diseases 3 and Kidney International 4
The American College of Rheumatology suggests using lower starting doses in patients with renal impairment, as recommended by the Annals of the Rheumatic Diseases 3
Supportive care, including close monitoring of liver function and management of complications, is crucial in improving outcomes 1, 2

Consider genetic testing for HLA-B*58:01 in high-risk populations, such as those of Korean, Han-Chinese, or Thai descent, when prescribing allopurinol, as recommended by the American College of Physicians 1
Monitor liver function tests periodically, especially in the first few months, and educate patients about early signs of hypersensitivity reactions, such as skin changes, fever, or signs of liver dysfunction 1, 2
Dose adjustments based on creatinine clearance and lower starting doses in patients with renal impairment can minimize the risk of adverse reactions, as recommended by the American Society of Clinical Oncology 5
Regular monitoring of renal function and liver function tests for patients with pre-existing liver disease can help identify potential issues early on, as recommended by Praxis Medical Insights 6

Uricosuric agents, such as probenecid and sulphinpyrazone, may be considered as alternative options for patients with liver concerns or allopurinol intolerance, similar to recommendations from the European League Against Rheumatism 2
Benzbromarone, primarily metabolized by the liver, carries a small risk of hepatotoxicity and may be considered as an alternative option 2
Significant interactions requiring dose adjustments include azathioprine and 6-mercaptopurine, which require 65-75% dose reduction when used with allopurinol, as well as increased risk of skin rash with ampicillin/amoxicillin and hypersensitivity with thiazide diuretics in patients with renal dysfunction 5

Patient education about early signs of hypersensitivity, such as skin changes, fever, or signs of liver dysfunction, is critical for preventing progression to severe adverse reactions 1
Periodic liver function tests and complete blood counts are recommended during the early stages of allopurinol therapy, especially in high-risk populations 3, 2
Complete blood counts, especially during the first few months of therapy, are crucial for monitoring patients on allopurinol, and genetic testing for HLA-B*58:01 in high-risk populations can help prevent hypersensitivity reactions 1